The DOI matches its Crossref record; 208 of the 208 references it cites were found in a registry or an index.
Review: Systemic inflammation andAlzheimer's disease
Abstract
There is a great deal of evidence suggesting an important role for systemic inflammation in the pathogenesis of A lzheimer's disease. The role of systemic inflammation, and indeed inflammation in general, is still largely considered to be as a contributor to the disease process rather than of aetiological importance although there is emerging evidence to suggest that its role may predate the deposition of amyloid. Therapies aimed at reducing inflammation in individuals with mild cognitive impairment and A lzheimer's disease have been disappointing and have largely focused on the need to ameliorate central inflammation with little attention to the importance of dampening down systemic inflammation. Novel approaches in this area require a greater understanding of the effects of systemic inflammation on the development and progression of A lzheimer's disease and of the communicating pathways between the systemic and central innate immune systems.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although the genetic susceptibility, numerous findings support the involvement in AD pathogenesis of other mechanisms such as inflammation [95], imbalance among production and removal of ROS [96], mitochondrial dysfunction [82], in addition to the β-amyloid cascade [97] and the deficiency of central cholinergic neurotransmitters [98] on which are based most of anti-AD drugs so far approved.”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [95]
In the citing paper
“Crosstalk between systemic and central innate immune systems by the release of inflammatory mediators is observed in AD (Holmes, 2013).”
From The impact of microglial activation on blood-brain barrier in brain diseases (2014) · cites this paper as Holmes, 2013
Citations
Cites
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Type 2 diabetes as an inflammatory disease
Donath, M. Y., & Shoelson, S. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2925 · Cited by 3,737
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Self-citationCyclooxygenase in biology and disease
Dubois, R. N., Abramson, S. B., Crofford, L., Gupta, R., Simon, L. S., Putte, L., & Lipsky, P. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.12.1063 · Cited by 2,606
High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal
Lotze, M. T., & Tracey, K. J. (2005) · Nature reviews. Immunology · doi:10.1038/nri1594 · Cited by 2,490
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Biological basis of the behavior of sick animals
Hart, B. L. (1988) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(88)80004-6 · Cited by 2,223
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
Franceschi, C., Capri, M., Monti, D., Giunta, S., Olivieri, F., Sevini, F., Panourgia, M. P., Invidia, L., Celani, L., Scurti, M., et al. (2007) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2006.11.016 · Cited by 2,087
Local self-renewal can sustain CNS microglia maintenance and function throughout adult life
Ajami, B., Bennett, J. L., Krieger, C., Tetzlaff, W., & Rossi, F. M. V. (2007) · Nature Neuroscience · doi:10.1038/nn2014 · Cited by 1,643
Research works printed but not linked: 1
- Bohac D, 2002, A 24‐week randomized, double‐blind, placebo‐controlled study of the efficacy and tolerability of TNFR: Fc (etanercept) in the treatment of dementia of the Alzheimer type, Neurobiol Aging, 23, 315
Cited by
Sorted by citations
The impact of microglial activation on blood-brain barrier in brain diseases
da Fonseca, A. C. C., Matias, D., Garcia, C., Amaral, R., Geraldo, L. H., Freitas, C., & Lima, F. R. S. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00362 · Cited by 572
Chen, S. G., Stribinskis, V., Rane, M. J., Demuth, D. R., Gozal, E., Roberts, A. M., Jagadapillai, R., Liu, R., Choe, K., Shivakumar, B., et al. (2016) · Scientific Reports · doi:10.1038/srep34477 · Cited by 463
TLR4 Cross-Talk With NLRP3 Inflammasome and Complement Signaling Pathways in Alzheimer's Disease
Yang, J., Wise, L., & Fukuchi, K.-I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00724 · Cited by 387
Mechanisms of Molecular Mimicry Involving the Microbiota in Neurodegeneration
Friedland, R. P. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142841 · Cited by 338
The dual roles of cytokines in Alzheimer’s disease: update on interleukins, TNF-α, TGF-β and IFN-γ
Zheng, C., Zhou, X.-W., & Wang, J.-Z. (2016) · Translational Neurodegeneration · doi:10.1186/s40035-016-0054-4 · Cited by 292
Metadata
- Authors
- Holmes, C.
- Affiliations
- Moorgreen Hospital (GB)
- Corresponding author
- Holmes, C.
- ORCID
- Holmes, C.
- Venue
- Neuropathology and Applied Neurobiology
- Publisher
- Wiley
- Published
- 2013-01-22
- Volume
- 39
- Issue
- 1
- Pages
- 51-68
- ISSN
- 0305-1846 (ISSN-L)
- 1365-2990
- OpenAlex
- W1916976076
- Semantic Scholar
- 22fc4893fe1c0cf60f5834083c9fe4f5159933fd
- Cited by
- 356
- References
- 208
- Citations by year
- 2026: 17 · 2025: 12 · 2024: 29 · 2023: 52 · 2022: 48 · 2021: 33 · 2020: 38 · 2019: 32 · 2018: 23 · 2017: 24 · 2016: 15 · 2015: 16 · 2014: 11 · 2013: 4
- FWCI
- 0.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neuropathology and Applied Neurobiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alzheimer Society
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- systemic inflammation, Alzheimer's disease, pathogenesis, amyloid deposition, mild cognitive impairment, anti-inflammatory therapy, innate immune system, neuroinflammation
- MeSH terms
- Alzheimer Disease, Animals, Humans, Inflammation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
